PRISM: determination of the performance characteristics of ReQuest in practice in the stepped down management of GORD [gastro-oesophageal reflux disease]
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Pantoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Acronyms PRISM
- Sponsors Fougera Pharmaceuticals
- 04 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
- 07 Jul 2007 New trial record.